65,437 trials
Follicular Lymphoma · Marginal Zone Lymphoma · Mantle Cell Lymphoma
Primary: All Phase I-II Participants: Overall Response Rate (ORR) — 28 percentage of participants
Hypophosphatasia
Primary: Number of Participants With Adverse Events (AEs) Including Injection Site Reactions (ISRs) and Injection Associated Reactions (IARs) — 9; 2; 0 Participants
Anxiety Disorders · Generalized Anxiety Disorder
Primary: Response Using Clinical Global Impressions-Improvement Scale (CGI-I) — 51; 69 participants
Myopia
Primary: Comfort — 8.90; 9.03; 8.70; 8.74 units on a scale
Brain and Central Nervous System Tumors
Primary: Overall Survival — 15.6; 19.3 Months — p=.222
Palatal Wound
Primary: Change in the Remaining Wound Area (RWA) — 62.91; 50.15; 65.74; 29.86 Square millimeters
Cardiac Event
Primary: Establishment of a Dataset to Create an Algorithm to Measure Cardiac Output — 75; 2 Participants
Lung Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Number of Patients Experiencing a DLT — 0; 1; 0; 0 Participants
Cancer · Prostate Neoplasms
Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g
Ovarian Cancer · Fallopian Tube Cancer
Primary: Median Time to Treatment Termination (TTT) — 78 days
Astigmatism
Primary: Overall Fit Acceptance — 3.8; 3.5; 3.7; 3.8 units on a scale
Restenosis · Peripheral Vascular Disease
Primary: Acute Procedural Success — 29 limbs
Lung Cancer · Radiation Toxicity
Primary: Overall Survival — 28.7; 20.3; 25.0; 24.0 months — p=0.0042
Smoking Cessation
Primary: Biochemically Confirmed (Exhaled CO ≤ 10 Ppm) Self-reported Continuous Abstinence at 26 Weeks. — 26; 23 Participants
Diphtheria · Pertussis · Tetanus
Primary: Geometric Mean Fold Rise in Serum Immunoglobulin G (IgG) by ELISA at Week 2 — 4.8; 8.6; 21.6; 22.4 Fold Rise